Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Added to Insulin Icodec in Type 2 Diabetes
2022-502717-28-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of semaglutide and insulin icodec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Change in glycated haemoglobin (HbA1c), Change in mean 7-point self-measured plasma glucose (SMPG) profiles and 2 more. Started Aug 2023; status: completed.
02
Drugs
semaglutideinsulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-502717-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502717-28-00.